MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as ...
A Phase 3 study compares P1101 to Anagrelide (ANA) as second-line treatments for high-risk essential thrombocythemia (ET) patients intolerant or resistant to hydroxyurea. The study aims to assess long-term safety and efficacy, with 101 patients randomized globally. Results will offer first evidence on P1101's effectiveness versus ANA.
Reference News
MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as ...
A Phase 3 study compares P1101 to Anagrelide (ANA) as second-line treatments for high-risk essential thrombocythemia (ET) patients intolerant or resistant to hydroxyurea. The study aims to assess long-term safety and efficacy, with 101 patients randomized globally. Results will offer first evidence on P1101's effectiveness versus ANA.